Skip to main content
    S

    Stoke Therapeutics Inc (STOK)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $24.61
    +1.35 (+5.80%)

    Market Cap: $1.50B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    66%(19/29)
    Avg Surprise
    +60.81%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.91
    Range$-1.03 - $-0.70
    12 analysts
    EPS Revisions
    1
    0
    7d
    1
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.81-12.6%
    60d ago$-0.91-0.3%
    30d ago$-0.91-0.1%
    7d ago$-0.91-0.1%
    Current$-0.91
    Revenue Consensus
    $8M
    Range$2M - $18M
    13 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.11
    Range$-1.44 - $-0.62
    12 analysts
    Revenue Consensus
    $14M
    Range$1M - $32M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.11---
    Sep 26EST
    		-$-0.91---
    Jun 26
    Reported Aug 3
    		$-0.93$-0.82-13.41%Miss-132.5%
    Mar 26
    Reported May 7
    		$-0.79$-0.82+3.66%Beat-141.6%
    Dec 25
    Reported Mar 16
    		$-0.97$-0.71-36.04%Miss-438.9%
    Sep 25
    Reported Nov 4
    		$-0.65$-0.57-14.04%Miss-38.3%
    Jun 25
    Reported Aug 12
    		$-0.40$-0.54+25.93%Beat+13.0%
    Mar 25
    Reported May 13
    		$1.90$-0.09+2211.11%Beat+433.3%
    Dec 24
    Reported Mar 18
    		$-0.18N/A+66.05%Beat+70.0%
    Sep 24
    Reported Nov 5
    		$-0.47$-0.54+12.96%Beat+14.5%
    Jun 24
    Reported Aug 7
    		$-0.46$-0.56+17.86%Beat+33.3%
    Mar 24
    Reported May 6
    		$-0.57$-0.61+6.56%Beat-7.5%
    Dec 23
    Reported Mar 25
    		$-0.60$-0.63+4.76%Beat+7.7%
    Sep 23
    Reported Nov 7
    		$-0.55$-0.64+14.06%Beat+16.7%
    Jun 23
    Reported Aug 7
    		$-0.69$-0.66-4.55%Miss-9.5%
    Mar 23
    Reported May 4
    		$-0.53$-0.71+25.35%Beat+19.7%
    Dec 22
    Reported Mar 6
    		$-0.65$-0.70+7.14%Beat+1.5%
    Sep 22
    Reported Nov 14
    		$-0.66$-0.68+2.94%Beat-8.2%
    Jun 22
    Reported Aug 8
    		$-0.63$-0.69+8.70%Beat-5.0%
    Mar 22
    Reported May 10
    		$-0.66$0.13-607.69%Miss-43.5%
    Dec 21
    Reported Mar 10
    		$-0.66$-0.62-6.45%Miss-57.1%
    Sep 21
    Reported Nov 8
    		$-0.61$-0.55-10.91%Miss-48.8%
    Jun 21
    Reported Aug 10
    		$-0.60$-0.46-30.43%Miss-53.8%
    Mar 21
    Reported May 10
    		$-0.46$-0.44-4.55%Miss-35.3%
    Dec 20
    Reported Mar 9
    		$-0.42$-0.42+0.00%Beat-366.7%
    Sep 20
    Reported Nov 12
    		$-0.41$-0.43+4.65%Beat-57.7%
    Jun 20
    Reported Aug 10
    		$-0.39$-0.36-8.33%Miss+74.7%
    Mar 20
    Reported May 15
    		$-0.34$-0.36+5.56%Beat+95.1%
    Dec 19
    Reported Feb 23
    		$-0.09N/A+70.00%Beat-
    Sep 19
    Reported Nov 12
    		$-0.26$-0.28+7.14%Beat-
    Jun 19
    Reported Aug 14
    		$-1.54$-1.63+5.52%Beat-
    Mar 19
    Reported Jun 19
    		$-6.89$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-7.37EV/EBITDAN/A
    Price/FCF-8.99xFCF Yield-11.12%
    Profitability
    Profit Margin0.00%Operating Margin-702.00%
    ROE-61.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio7.69xQuick Ratio7.69x
    Trading Statistics
    Beta1.26Avg Volume988.04K
    52-Week High$40.2252-Week Low$20.32

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.28
    SMA 20$25.40
    SMA 50$28.86
    SMA 200$31.28
    EMA 10$24.36
    EMA 20$25.43
    EMA 50$27.60
    EMA 200$28.94

    MACD

    Line: -1.45Signal: -1.45Hist: 0.01

    ADX

    ADX: 36.8+DI: 17.9-DI: 34.3

    Aroon & PSAR

    Aroon Up4.0
    Aroon Down96.0
    PSAR$25.93

    Bollinger Bands

    Upper Band$28.73
    Lower Band$22.08
    %B Position2619%(Upper)
    Band Width0.38

    RSI (14-Day)

    Neutral
    42.0

    Momentum Oscillators

    Stoch %K28.6
    Stoch %D20.6
    Williams %R-44.8
    ROC (10d)-5.4%
    Momentum-1.40
    CCI (20d)-64.1
    MFI (14d)46.1

    Volatility Measures

    ATR (14d)$1.29(5.2%)
    StdDev (20d)1.66
    Hist Vol60.4%(High)

    Volume Flow

    VWAP$24.23
    OBV47.6M
    AD Line18.0M
    CMF (20d)-0.149

    Volume Metrics

    Avg Vol (20d)1.0M
    Vol Ratio0.7x
    VWMA (20d)$25.53

    Pivot Points

    R3$25.03
    R2$24.19
    R1$23.73
    Pivot Point$22.89
    S1$22.42
    S2$21.58
    S3$21.12

    Advanced Oscillators

    TSI-32.15
    Ultimate Osc52.5
    KST-176.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.32M$6.23M$1.40M$10.63M$13.82M$158.57M$22.61M$4.89M$4.83M$4.22M$2.80M$3.31M
    Cost of Revenue$0$0$1.05M$0$0$0$1.11M$0$0$0$1.22M$0
    Gross Profit$9.32M$6.23M$1.40M$10.63M$13.82M$158.57M$22.61M$4.89M$4.83M$4.22M$2.80M$3.31M
    Operating Expenses$74.75M$59.65M$62.84M$53.72M$41.12M$47.33M$36.27M$34.90M$34.17M$32.59M$32.39M$30.54M
    R&D$49.50M$39.67M$41.70M$37.70M$25.86M$32.68M$23.42M$22.20M$21.14M$22.37M$21.78M$20.27M
    SG&A$25.25M$19.97M$21.15M$16.03M$15.26M$14.65M$12.85M$12.69M$13.04M$10.22M$10.61M$10.27M
    Operating Income$-65,429,000$-53,418,000$-61,439,000$-43,091,000$-27,300,000$111.24M$-13,655,000$-30,003,000$-29,342,000$-28,372,000$-29,587,000$-27,234,000
    Interest Income$3.50M$3.40M$3.62M$3.46M$3.79M$2.89M$2.97M$3.54M$3.69M$2.43M$2.59M$2.65M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-61,618,000$-50,003,000$-57,934,000$-39,625,000$-23,483,000$114.16M$-10,482,000$-26,430,000$-25,695,000$-26,374,000$-26,958,000$-24,542,000
    Income Tax Expense$0$0$0$-1,278,000$0$1.28M$0$0$0$0$0$0
    Net Income$-61,618,000$-50,003,000$-57,934,000$-38,347,000$-23,483,000$112.88M$-10,482,000$-26,430,000$-25,695,000$-26,374,000$-26,958,000$-24,542,000
    EBITDA$-65,032,000$-53,326,000$-61,695,000$-43,261,000$-26,299,000$111.25M$-13,710,000$-29,982,000$-29,131,000$-28,261,000$-29,010,000$-26,678,000
    EBIT$-65,121,000$-53,400,000$-61,549,000$-43,088,000$-27,272,000$111.27M$-13,454,000$-29,975,000$-29,390,000$-28,800,000$-29,545,000$-27,193,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about STOK

    News

    Liquidity Mapping Around (STOK) Price Events

    This article provides a liquidity mapping analysis for Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting weak near and mid-term sentiment and a neutral long-term outlook. It presents AI-generated trading strategies...

    Stock Traders Daily•10/15/26•Somewhat-Bearish

    Stoke presents STK-002 data. Stoke Therapeutics stock is valued at USD 1.5 billion

    Stoke Therapeutics presented new data for its STK-002 drug candidate at the American Academy of Ophthalmology meeting. The company's stock was trading at EUR 20.83 on October 15, 2026...

    ad-hoc-news.de•10/15/26•Somewhat-Bullish

    Stoke Therapeutics (STOK) Puts STK 002 Data In Focus Following An Undervalued Narrative

    Stoke Therapeutics (STOK) recently presented new clinical data for its RNA-based therapy STK-002 for Autosomal Dominant Optic Atrophy at the AAO 2026 meeting. Despite a recent share price decline...

    Simply Wall Street•10/14/26•Neutral

    Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell?

    Stoke Therapeutics (NASDAQ:STOK) saw its shares decline by 7.1% in mid-day trading. Despite this drop and missing EPS expectations...

    MarketBeat•10/13/26•Somewhat-Bearish

    Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October

    This article reports that Jonathan Allan, General Counsel & Corporate Secretary for Stoke Therapeutics Inc., filed a Form 4 for the 2nd of October. A Form 4 is a document filed with the SEC by company insiders to report...

    Investing.com India•10/13/26•Neutral

    STOK Valuation and Fair Value

    P/E
    -7.4x
    Forward P/E
    204.1x
    P/FCF
    -9.0x
    P/B
    4.7x
    See GNG's fair value

    STOK Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -702.0%
    Net margin
    0.0%
    ROE
    -61.1%
    FCF margin
    -654.9%
    FCF yield
    -11.1%

    STOK Competitors

    CompanyTicker
    Eton Pharmaceuticals IncETON
    Innoviva IncINVA
    Phibro Animal Health CorporationPAHC
    UltragenyxRARE
    Structure Therapeutics Inc. American Depositary SharesGPCR
    Certara IncCERT
    RAPT Therapeutics IncRAPT
    Immunocore Holdings LtdIMCR

    Sector: Healthcare

    STOK Analyst Ratings

    Consensus
    Buy
    Analysts
    14
    Strong Buy
    2
    Buy
    12
    Hold
    0
    Sell
    0
    Strong Sell
    0

    STOK Bull Case vs Bear Case

    Bull case

    • 100.0% of STOK's analyst ratings are Buy or Strong Buy.

    Bear case

    • STOK's quarterly revenue changed -32.5% year over year.

    STOK Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    282.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.91
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 3 down

    Frequently Asked Questions About STOK

    Does STOK pay dividends?

    Stoke Therapeutics Inc (STOK) does not currently pay a regular dividend.

    What is STOK's market cap?

    Stoke Therapeutics Inc (STOK) has a market capitalization of $1.50B with a current stock price of $24.61.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In